SEIKAGAKU CORPORATION Logo

SEIKAGAKU CORPORATION

A research pharma company using glycoscience to develop drugs for orthopedic & ophthalmic diseases.

4548 | T

Overview

Corporate Details

ISIN(s):
JP3414000004
LEI:
Country:
Japan
Address:
千代田区丸の内一丁目6番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Seikagaku Corporation is a research-driven pharmaceutical company specializing in glycoscience. The company engages in the research, development, manufacture, and sale of pharmaceuticals and medical devices, with a primary focus on glycoconjugates like glycosaminoglycans (GAGs). Its main therapeutic areas include orthopedic disorders and ophthalmic diseases, offering products such as joint function improving agents. Seikagaku oversees its product lifecycle from in-house drug discovery and clinical trials to regulatory approval and commercial production, leveraging its specialized expertise in the field of complex carbohydrates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 06:56
Registration Form
確認書
Japanese 8.1 KB
2025-11-12 06:55
Interim Report
半期報告書-第80期(2025/04/01-2026/03/31)
Japanese 196.8 KB
2025-06-24 08:14
Post-Annual General Meeting Information
臨時報告書
Japanese 23.0 KB
2025-06-23 06:58
Governance Information
内部統制報告書-第79期(2024/04/01-2025/03/31)
Japanese 22.6 KB
2025-06-23 06:57
Registration Form
確認書
Japanese 8.0 KB
2025-06-23 06:56
Annual Report
有価証券報告書-第79期(2024/04/01-2025/03/31)
Japanese 1.1 MB
2024-11-12 06:58
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-11-12 06:56
Interim Report
半期報告書-第79期(2024/04/01-2025/03/31)
Japanese 191.1 KB
2024-06-27 06:53
Governance Information
内部統制報告書-第78期(2023/04/01-2024/03/31)
Japanese 21.9 KB
2024-06-27 06:52
Registration Form
確認書
Japanese 8.0 KB
2024-06-27 06:51
Annual Report
有価証券報告書-第78期(2023/04/01-2024/03/31)
Japanese 1.1 MB
2024-06-25 04:10
Post-Annual General Meeting Information
臨時報告書
Japanese 23.7 KB
2024-02-14 08:57
Quarterly Report
四半期報告書-第78期第3四半期(2023/10/01-2023/12/31)
Japanese 165.1 KB
2024-02-14 08:57
Report Publication Announcement
確認書
Japanese 8.0 KB
2023-11-14 05:06
Report Publication Announcement
確認書
Japanese 8.0 KB

Automate Your Workflow. Get a real-time feed of all SEIKAGAKU CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SEIKAGAKU CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SEIKAGAKU CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

VivoSim Labs, INC. Logo
Offers 3D human tissue models for predictive toxicology testing to accelerate drug discovery.
United States of America
VIVS
Develops innovative, non-narcotic drugs for pain and central nervous system (CNS) diseases.
South Korea
082800
VOLITIONRX LTD Logo
Develops epigenetic blood tests for early cancer and sepsis detection in human/veterinary markets.
United States of America
VNRX
vTv Therapeutics Inc. Logo
Develops oral small molecule drugs for type 1 diabetes and other chronic conditions.
United States of America
VTVT
VYNE Therapeutics Inc. Logo
Clinical-stage biopharma developing novel therapies for immuno-inflammatory diseases.
United States of America
VYNE
WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo
Develops gastrointestinal and ophthalmic drugs for the health challenges of an aging society.
Japan
4512
Wave Life Sciences Ltd. Logo
Developing RNA-based medicines for severe genetic diseases like DMD and Huntington's disease.
United States of America
WVE
WELLBIOTEC CO.,LTD Logo
Diversified in biopharma, EV chargers, and lithium supply for batteries.
South Korea
010600
Werewolf Therapeutics, Inc. Logo
Developing tumor-activated immunotherapies for a localized immune attack on cancer.
United States of America
HOWL
WHANIN PHARM CO.,LTD Logo
Develops and sells pharmaceuticals, specializing in CNS, cardiovascular, and GI drugs.
South Korea
016580

Talk to a Data Expert

Have a question? We'll get back to you promptly.